Rachad Nasr, Doriane Lorendeau, Ruttiros Khonkarn, Lauriane Dury, Basile Pérès, Ahcène Boumendjel, Jean-Claude Cortay, Pierre Falson, Vincent Chaptal, Hélène Baubichon-Cortay
Scientific reports 2020 May 06The transporter Multidrug Resistance Protein 1 (MRP1, ABCC1) is implicated in multidrug resistant (MDR) phenotype of cancer cells. Glutathione (GSH) plays a key role in MRP1 transport activities. In addition, a ligand-stimulated GSH transport which triggers the death of cells overexpressing MRP1, by collateral sensitivity (CS), has been described. This CS could be a way to overcome the poor prognosis for patients suffering from a chemoresistant cancer. The molecular mechanism of such massive GSH transport and its connection to the other transport activities of MRP1 are unknown. In this context, we generated MRP1/MRP2 chimeras covering different regions, MRP2 being a close homolog that does not trigger CS. The one encompassing helices 16 and 17 led to the loss of CS and MDR phenotype without altering basal GSH transport. Within this region, the sole restoration of the original G1228 (D1236 in MRP2) close to the extracellular loop between the two helices fully rescued the CS (massive GSH efflux and cell death) but not the MDR phenotype. The flexibility of that loop and the binding of a CS agent like verapamil could favor a particular conformation for the massive transport of GSH, not related to other transport activities of MRP1.
Rachad Nasr, Doriane Lorendeau, Ruttiros Khonkarn, Lauriane Dury, Basile Pérès, Ahcène Boumendjel, Jean-Claude Cortay, Pierre Falson, Vincent Chaptal, Hélène Baubichon-Cortay. Molecular analysis of the massive GSH transport mechanism mediated by the human Multidrug Resistant Protein 1/ABCC1. Scientific reports. 2020 May 06;10(1):7616
PMID: 32377003
View Full Text